Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Middle Aged (0):
Recent article
Middle Aged
Abstract
Clinical practice guidelines recommend maintaining serum potassium levels between 4.0 and 5.0 mEq/L in patients with acute myocardial infarction (AMI). These guidelines are based on small studies that associated low potassium levels with ventricular arrhythmias in the pre-β-blocker...
|
PMID: 22235086
PDF is available here.
PDF is available here.
| < More recent | Older article > |
Abstract
Marijuana smoke contains many of the same constituents as tobacco smoke, but whether it has similar adverse effects on pulmonary function is unclear.
To analyze associations between marijuana (both current and lifetime exposure) and pulmonary function....
|
PMID: 22235088
PDF is available here.
PDF is available here.
Abstract
Links are well established between both family history of diabetes and reduced birthweight and increased risk of diabetes in adulthood.
1) To investigate the influence of parental history of type 2 diabetes (T2DM) on offspring birthweight and adult offspring glucose t...
|
PMID: 21916855
PDF is available here.
PDF is available here.
Abstract
We present the first analysis of age-at-onset in the NIMH LOAD sample that allows for both a multilocus trait model and genetic heterogeneity among the contributing sites, while at the same time accommodating age censoring, effects of known genetic covariates, and full pedigree and marker informatio...
|
PMID: 21812099
PDF is available here.
PDF is available here.
Abstract
We experienced a case of a peritoneal dialysis patient with chronic hepatitis C who was successfully treated with PEG-IFN monotherapy. A 50-year old man was undergoing peritoneal dialysis because of diabetic nephropathy. Considering that his HCV genotype was 2, we decided to treat him with PEG-IFN a...
|
PMID: 21873827
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
Nature Medicine (17)12 2011
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In...
|
PMID: 22101764
PDF is available here.
PDF is available here.
New England Journal of Medicine (365)19 2011
Abstract
We conducted a matched case-control study and a recipe-based restaurant cohort study, along with environmental, trace-back, and trace-forward investigations, to determine the source of infection.
The case-control study included 26 case subjects with the hemolytic-uremic syndrome and...
|
PMID: 22029753
PDF is available here.
PDF is available here.
New England Journal of Medicine (365)19 2011
Abstract
We describe an outbreak of gastroenteritis and the hemolytic-uremic syndrome caused by Shiga-toxin-producing Escherichia coli in Germany in May, June, and July, 2011. The consumption of sprouts was identified as the most likely vehicle of infection.
We analyzed data from reports in G...
|
PMID: 21696328
PDF is available here.
PDF is available here.
Abstract
We describe the magnitude, kinetics, and nature of the virus-specific T cell response using intracellular gamma interferon (IFN-γ) staining and fluorochrome-labeled major histocompatibility complex (MHC) class I-peptide complexes. We demonstrate that influenza virus-infected patients develop recall...
|
PMID: 21917970
PDF is available here.
PDF is available here.
Abstract
We hypothesized that, with hypertension, localized iNOS inhibition would restore vasodilation in response to NO-dependent stimuli, and iNOS expression would be increased and phosphorylated vasodilator-stimulated phosphoprotein would be decreased. For, in vivo protocols, 4 intradermal microdialysis f...
|
PMID: 21931069
PDF is available here.
PDF is available here.
Abstract
We established a new limited sampling strategy to assess CYP3A activity and evaluated the time course of reversible (voriconazole) and irreversible (ritonavir) CYP3A inhibition. In this randomized trial, two groups, each with eight healthy participants, received CYP3A inhibitors voriconazole or riton...
|
PMID: 21937987
PDF is available here.
PDF is available here.
Abstract
Although extensive evidence support the key role of adipokines in cartilage homeostasis, contradictory data have been found for their expression and their effects in chondrocytes. This study was then undertaken to determine whether a phenotypic modulation may affect the expression of adipokines and t...
|
PMID: 21935928
PDF is available here.
PDF is available here.
Abstract
Although feeling bothered by the sexual unresponsiveness of an intimate partner was significantly associated with both women's and men's depressive symptoms, the moderating effect of the partner's supportiveness was significant only for women. Discussion. The results suggest that gender is a key d...
|
PMID: 21918124
PDF is available here.
PDF is available here.